News and Press Releases
Press releases
Theralase Release’s 2Q2023 Interim Financial Statements
Toronto, Ontario – August 29th, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clini...
0
Theralase® Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements
In the Performance to Primary, Secondary and Tertiary Objectives second table the 90 day results were misstated and has been corrected in this pres...
0Theralase® Appoints Roger DuMoulin-White as President and Chief Executive Officer
Toronto, Ontario – May 24, 2023,Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical sta...
0
Theralase® Provides Update on Phase II Bladder Cancer Study
For the primary objective, 65% of Evaluable Patients (Patients evaluated by a Principal Investigator (“PI”)) achieved a Complete Response (“C...
0Theralase Releases FY2022 Audited Financial Statements
Toronto, Ontario – April 26, 2023, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical st...
0Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium
Toronto, Ontario – February 23, 2023,Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinica...
0Theralase® Awarded TSX Venture 50 ™ Recognition as a Top Performing Company
Toronto, Ontario – February 21, 2023,Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinic...
0Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the AUA Annual Meeting
Toronto, Ontario – February 2, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinica...
0Theralase® Phase II NMIBC Clinical Study (Interim) Data to Presented at the ASCO GU Cancer Symposium
Toronto, Ontario – January 25, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinica...
0Theralase ® Announces Warrant Extension
Toronto, Ontario – January 5, 2023, Theralase® Technologies Inc. (“Theralase” or “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage ph...
0in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
